2017 Companion Diagnostics Market Embraces Advancements

September Offer –
Flat 20% discount on purchase of this report from 15th to 30th September @ https://www.researchtrades.com/discount/1090943

For more offers post 30th September, kindly contact us.
Contact No. : +16269994607 (US)/ +91 7507349866 (IND)
Email: sales@researchtrades.com

Report Overview:
The Global Companion Diagnostic market accounted for USD 5,813 million in 2016 and is estimated to account for USD 26,064 million in 2021 growing at a CAGR of 35%. It is a test that is done to identify the genetic profile of a patient suffering from cancer or other inherited disease for which a specific form of treatment (therapeutics involving monoclonal bodies in most cases) could be administered. It helps in the reduction of the side effects and also increases the efficacy of a particular drug.
Companion diagnostic is a type of in-vitro diagnostic that has seen rapid acceptance among most healthcare professionals because of its sensitivity to predict a drug response and also as it helps to categorize the population of people who will respond to a particular drug. It has seen wide acceptance for indications of different forms of cancer like lung cancer, colorectal cancer, melanoma and others.
The global companion diagnostic market is driven by various factors like manufacturers promoting personalized medicine and targeted therapy, increase cases of adverse drug reaction and co development of drug and diagnostic technology development. However the market is restrained by factors like high cost of drug development and associated clinical trials and reimbursement issues among many countries.

Get exclusive sample copy @ https://www.researchtrades.com/request-sample/1090943

The global companion diagnostic market is segmented based on the technology used, the applications and the indications. Based on the technology used the market is further segmented into immunohistochemistry, polymerase chain reaction, in-situ hybridization, real time PCR, gene sequencing and others. Based on indications the market is segmented into lung cancer, breast cancer, colorectal cancer, leukemia, melanoma and others.
Based on geography the market is further segmented into North America (USA, Canada, and Mexico), Europe (UK, France, Germany, Spain, Portugal, Italy, Scandinavia, and BENELUX), Asia Pacific (India, China, Japan, Australia, Netherlands, and South Korea), Latin America (Brazil, Argentina), Middle East and Africa (GCC, South Africa and other countries).

Key elements for this report:
1. Introduction
1.1 Report Description
1.2 Study Assumptions
1.3 Market Definitions
1.4 Companion Diagnostics Introduction
1.4.1 Context and Background
1.4.2 Difference between In Vitro Diagnostics and Companion Diagnostics
1.4.3 Labeling Considerations
1.4.4 Classical Drug & In Vitro Diagnostics Development
1.4.5 Companion Diagnostics Regulatory Framework
1.4.5.1 United States Regulation
1.4.5.2 Europe Regulation
1.4.5.3 Rest of World Regulation

2. Research Approach and Methodology
2.1 Introduction
2.2 Analysis Methodology
2.3 Study Phases
2.3.1 Secondary Research
2.3.2 Discussion Guide
2.3.3 Market Engineering & Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
…
Browse this report @ https://www.researchtrades.com/report/global-companion-diagnostics-market-industry-analysis-size-share-growth-trends-and-forecasts-2016-2021/1090943

Who we are:
Research Trades has team of experts who works on providing exhaustive analysis pertaining to market research on a global basis. This comprehensive analysis is obtained by a thorough research and study of the ongoing trends and provides predictive data regarding the future estimations, which can be utilized by various organizations for growth purposes.

We distribute customized reports that focus on meeting the client’s specific requirement. Our database consists of a large collection of high-quality reports obtained using a customer-centric approach, thus providing valuable research insights.

This release was published on openPR.